A Study of LY2784544 in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01577355
Recruitment Status : Completed
First Posted : April 13, 2012
Last Update Posted : July 3, 2012
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
This is a single dose study of radiolabelled LY2784544 in healthy male subjects to study the absorption, distribution, metabolism and excretion of LY2784544. This study is for research purposes only and is not intended to treat any medical condition.

Condition or disease Intervention/treatment Phase
Healthy Male Volunteers Radiation: Drug Phase 1

Detailed Description:
This study is approximately 10 days long, (minimum 5 days, maximum 15 days) not including screening or follow up. Screening is required within 28 days prior to the first dose of study drug and follow up is required at least 7 days after discharge from the clinical research unit.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects
Study Start Date : April 2012
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Arm Intervention/treatment
Experimental: [C14]-LY2784544
Single 30 mg oral dose containing 100 micro curies of LY2784544
Radiation: Drug
Single 30 mg oral dose containing 100 micro curies of LY2784544

Primary Outcome Measures :
  1. Urinary and fecal excretion of LY2784544 radioactivity over time expressed as a percentage of the total radioactive dose administered [ Time Frame: Predose up to 14 days post dose ]

Secondary Outcome Measures :
  1. Plasma pharmacokinetics of LY2784544 and radioactivity maximum observed concentration (Cmax) [ Time Frame: Predose up to 14 days post dose ]
  2. Plasma pharmacokinetics of LY27854544 and radioactivity time of maximum observed concentration (tmax) [ Time Frame: Predose up to 14 days post dose ]
  3. Plasma pharmacokinetics of LY2784544 and radioactivity area under the concentration-time curve from time zero to the last timepoint with a measurable concentration (AUC 0 to tlast) [ Time Frame: Predose up to 14 days post dose ]
  4. Relative abundance of LY2784544 and the metabolites of LY2784544 in urine and feces [ Time Frame: Predose up to 14 days post dose ]
  5. Relative abundance of LY2784544 and the metabolites of LY2784544 in plasma [ Time Frame: Predose up to 14 days post dose ]
  6. Plasma pharmacokinetics of LY2784544 and radioactivity half-life [ Time Frame: Predose up to 14 days postdose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Overtly healthy males as determined by medical history and physical examination

    • Will either be sterile or, if sexually active, agree to use a reliable method of birth control from the day before dosing until 3 months after the end of the study
  • Have a body mass index (BMI) of 19 to 29 kg/m^2, inclusive
  • Have clinical laboratory test results within the normal reference range for the Clinical Research Unit (CRU) or results with acceptable deviations which are judged to be not clinically significant by the investigator
  • Normal blood pressure (BP) and heart rate (sitting) as determined by the investigator
  • Have venous access sufficient to allow for blood sampling as per the study requirements
  • Are reliable and willing to make themselves available for the duration of the study and are willing to abide by the CRU policies and procedures and study restrictions
  • Have given written informed consent approved by Lilly and the institutional review board (IRB) governing the CRU

Exclusion Criteria:

  • Are currently enrolled in, have completed, or discontinued within the last 30 days from a clinical study involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have known allergies to LY2784544 or related compounds
  • Have previously completed or withdrawn from this study or any other study investigating LY2784544
  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Have a history or evidence of significant active neuropsychiatric disease and in particular evidence of significant medical or psychiatric illness within the past 12 months or have suicidal risk at the time of screening in the opinion of the investigator
  • Have any other condition that in the opinion of the investigator would preclude participation in the study
  • Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
  • Show evidence of hepatitis C and/or positive hepatitis C antibody
  • Show evidence of hepatitis B and/or positive hepatitis B surface antigen
  • Use of herbal preparations containing St. John's Wort, kava, garlic, ginger, gingko biloba, or guarana within 14 days prior to admission or at any time during the study
  • Intent to use over-the-counter (OTC) medication or prescription medication within 7 days prior to dosing or at any time during the study
  • Consumption of grapefruit or grapefruit-containing foods or grapefruit-containing juices, Seville oranges or Seville orange juices, and star fruit or star fruit juices within 7 days prior to dosing or at any time during the study
  • Have an average weekly alcohol intake that exceeds 21 units per week or are unwilling to stop alcohol consumption for the duration of the study
  • Have donated blood of more than 500 mL within the last month
  • Have participated in a [14C]-study within the last 6 months prior to admission for this study. The total exposure from this study and the previous study must be within the Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR 361.1), less than 5000 millirems (mrem)/year whole body annual exposure
  • Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
  • Are currently smokers or users of tobacco or nicotine-replacement products within the 6 months prior to study entry
  • Baseline 12-lead electrocardiogram (ECG) with a corrected QT (Bazett's) interval of >450 msec and/or have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Have a history of congestive heart failure, unstable angina, myocardial infarction, or documented history of ventricular arrhythmia
  • Gastrointestinal disorders causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes
  • Evidence of active renal disease (e.g., diabetic renal disease, polycystic kidney disease) or creatinine clearance (CrCl) less than 70 mL/min
  • Urinalysis with ≥1+ protein or ≥1+ blood (unless attributable to an acute condition that is resolved prior to dosing)
  • Use of drugs with narrow therapeutic windows and that are also known substrates of Cytochrome P450 (CYP)1A2, CYP2B6, and CYP3A are specifically excluded
  • Use of antacids and proton pump inhibitors
  • Typically do not produce at least one bowel movement per day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01577355

United States, Wisconsin
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Responsible Party: Eli Lilly and Company Identifier: NCT01577355     History of Changes
Other Study ID Numbers: 14484
I3X-MC-JHTD ( Other Identifier: Eli Lilly and Company )
First Posted: April 13, 2012    Key Record Dates
Last Update Posted: July 3, 2012
Last Verified: July 2012